| Literature DB >> 18464053 |
O Moennikes1, P M Vanscheeuwijck, B Friedrichs, E Anskeit, G J Patskan.
Abstract
Cigarette smoke is a complex chemical mixture that causes a variety of diseases, such as lung cancer. With the electrically heated cigarette smoking system (EHCSS), temperatures are applied to the tobacco below those found in conventional cigarettes, resulting in less combustion, reduced yields of some smoke constituents, and decreased activity in some standard toxicological tests. The first generation of electrically heated cigarettes (EHC) also resulted in increased formaldehyde yields; therefore, a second generation of EHC was developed with ammonium magnesium phosphate (AMP) in the cigarette paper in part to address this increase. The toxicological activity of mainstream smoke from these two generations of EHC and of a conventional reference cigarette was investigated in two studies in rats: a standard 90-day inhalation toxicity study and a 35-day inhalation study focusing on lung inflammation. Many of the typical smoke exposure-related changes were found to be less pronounced after exposure to smoke from the second-generation EHC with AMP than to smoke from the first-generation EHC or the conventional reference cigarette, when compared on a particulate matter or nicotine basis. Differences between the EHC without AMP and the conventional reference cigarette were not as prominent. Overall, AMP incorporated in the EHC cigarette paper reduced the inhalation toxicity of the EHCSS more than expected based on the observed reduction in aldehyde yields.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18464053 PMCID: PMC2442902 DOI: 10.1080/08958370701813273
Source DB: PubMed Journal: Inhal Toxicol ISSN: 0895-8378 Impact factor: 2.724
FIG. 1Mainstream smoke generation and exposure for the EHC. Smoking machine, tubing and exposure chamber.
FIG. 3EECR estimation for atrophy of olfactory epithelium in the olfactory region of the nose at level 2. Male rats at the end of the inhalation period of the subchronic inhalation toxicity study. Data points with error bars (mean values with SE) represent the scoring of histopathological findings for the different exposure groups. For the 1R4F cigarette the concentration response curve is plotted on a μg TPM/L basis. Arrows indicate the estimation of the concentration of 1R4F MS causing an effect comparable to the one of the EHC MS. The EECR is calculated by dividing the corresponding 1R4F concentration through the EHC concentration.
Characterization of test atmospheres*: inhalation toxicity study
| Parameter | Sham | 1R4F-low | 1R4F-medium | 1R4F-high | EHC-CaCO3 | EHC-AMP |
|---|---|---|---|---|---|---|
| TPM (μg/l) | <0.9 | 79 ± 4 | 120 ± 5 | 161 ± 8 | 90 ± 5 | 87 ± 5 |
| Particle size, MMAD (μm) | — | 0.46 | 0.46 | 0.47 | 0.39 | 0.44 |
| GSD | — | 1.65 | 1.66 | 1.66 | 1.71 | 1.78 |
| Carbon monoxide (ppm) | <1.5 | 94 ± 5 | 141 ± 8 | 188 ± 9 | 28.7 ± 0.8 | 14.5 ± 0.7 |
| Nicotine (μg/l) | <0.03 | 5.9 ± 0.4 | 8.6 ± 0.6 | 11.2 ± 1.1 | 8.3 ± 0.7 | 7.3 ± 0.6 |
| Formaldehyde (ppm) | — | 0.12 ± 0.02 | 0.17 ± 0.03 | 0.22 ± 0.03 | 1.32 ± 0.10 | 0.16 ± 0.03 |
| Acetaldehyde (ppm) | — | 4.0 ± 0.3 | 5.9 ± 0.4 | 7.6 ± 0.6 | 5.3 ± 0.1 | 2.9 ± 0.2 |
| Acrolein (ppm) | — | 0.27 ± 0.03 | 0.40 ± 0.04 | 0.52 ± 0.03 | 0.42 ± 0.03 | 0.35 ± 0.03 |
Measured at breathing zone in the exposure chambers.
Values represent means ± standard deviations.
MMAD: mass-median aerodynamic diameter; GSD: geometric standard deviation.
Biomonitoring: inhalation toxicity study
| Parameter | Sex | Sham | 1R4F-low | 1R4F-medium | 1R4F-high | EHC-CaCO3 | EHC-AMP |
|---|---|---|---|---|---|---|---|
| Respiratory frequency (1/min) | M | 129 ± 8 | 152 ± 8 | 128 ± 5 | 121 ± 4 | 131 ± 9 | 125 ± 10 |
| F | 119 ±10 | 146 ± 10 | 111 ± 7 | 96 ± 6 | 100 ± 4 | 141 ± 5 | |
| Average inspiratory flow (ml/sec) | M | 8.7 ± 0.4 | 6.2 ± 0.4 | 5.4 ± 0.6 | 5.9 ± 0.4 | 6.0 ± 0.4 | 6.7 ± 0.6 |
| F | 7.1 ± 0.6 | 5.7 ± 0.6 | 4.7 ± 0.5 | 3.9 ± 0.6 | 4.7 ± 0.4 | 6.3 ± 0.4 | |
| COHb (%) | M | 0.64 ± 0.03 | 13.94 ± 0.30 | 19.5 ± 0.53 | 26.00 ± 0.65 | 4.65 ± 0.29 | 2.27 ± 0.07 |
| F | 0.85 ± 0.03 | 12.82 ± 0.33 | 20.38 ± 1.21 | 25.27 ± 0.57 | 4.91 ± 0.40 | 1.52 ± 0.06 | |
| Recovery of inhaled nicotine (%) | M | — (n.d.) | 73.2 ± 5.3 | 61.5 ± 6.8 | 76.0 ± 7.3 | 63.7 ± 5.7 | 60.4 ± 7.3 |
| F | — (n.d.) | 68.1 ± 9.1 | 88.3 ± 9.4 | 75.5 ± 3.9 | 68.4 ± 11.4 | 69.6 ± 4.7 |
Values represent means ± standard error.
Statistically significantly different from sham, p ≤ 0.05.
n.d.: not determined.
FIG. 2Body weight development of male rats in the subchronic inhalation toxicity study. Curves represent the mean body weight of sham- and MS-exposed groups.
Body weight and hematology after 90 days of exposure: inhalation toxicity study
| Groups | EECRs | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | Sex | Sham | 1R4F-Iow | lR4F-medium | lR4F-high | EHC-CaCO3 | EHC-AMP | EHC-CaCO3 | EHC-AMP |
| Body weight (g) | M | 395.8 ± 6.7 | 331.7 ± 11.8 | 339.7 ± 9.9 | 310.3 ± 10.1 | 309.0 ± 7.7 | 349.9 ± 10.8 | 1.99 | 0.61 |
| F | 212.4 ± 3.9 | 199.4 ± 3.8 | 204.5 ± 4.7 | 207.7 ± 5.2 | 202.1 ± 4.4 | 200.8 ± 5.9 | – | – | |
| Platelet count (109/l) | M | 977 ± 42 | 934 ± 43 | 817 ± 49 | 862 ± 32 | 851 ± 29 | 818 ± 38 | 1.62 | 2.26 |
| F | 921 ± 58 | 901 ± 38 | 886 ± 37 | 812 ± 23 | 880 ± 36 | 906 ± 26 | – | – | |
| Neutrophils in blood (109/l) | M | 0.87 ± 0.16 | 1.14 ± 0.19 | 1.48 ± 0.20 | 1.90 ± 0.30 | 1.39 ± 0.13 | 1.34 ± 0.36 | 1.24 | 1.21 |
| F | 0.45 ± 0.05 | 0.74 ± 0.10 | 1.09 ± 0.14 | 1.30 ± 0.13 | 1.04 ± 0.10 | 0.64 ± 0.08 | 1.34 | 0.61 | |
| Lymphocytes in blood (109/l) | M | 6.32 ± 0.54 | 3.74 ± 0.64 | 3.83 ± 0.54 | 3.91 ± 0.41 | 5.23 ± 0.56 | 4.82 ± 0.82 | – | – |
| F | 3.61 ± 0.45 | 3.33 ± 0.30 | 3.56 ± 0.42 | 3.75 ± 0.48 | 2.67 ± 0.22 | 3.79 ± 0.55 | – | – | |
Values represent means ± standard error.
Statistically significantly different from sham, p ≤ 0.05.
EECRs were calculated on an equal TPM basis.
–: no EECR calculated because data did not fit the criteria.
Clinical chemistry after 90 days of exposure: inhalation toxicity study
| Groups | EECRs | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | Sex | Sham | 1R4F-Iow | lR4F-medium | lR4F-high | EHC-CaCO3 | EHC-AMP | EHC-CaCO3 | EHC-AMP |
| Total cholesterol (mmol/1) | M | 2.0 ± 0.1 | 1.5 ± 0.1 | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.7 ± 0.1 | 1.8 ± 0.1 | – | – |
| F | 2.3 ± 0.2 | 1.6 ± 0.2 | 1.5 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.8 ± 0.1 | 1.75 | 0.68 | |
| Triglycerides (mmol/1) | M | 0.8 ± 0.1 | 0.7 ± 0.1 | 0.7 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | – | – |
| F | 1.1 ± 0.3 | 0.7 ± 0.1 | 0.5 ± 0.1 | 0.4 ± 0.0 | 0.5 ± 0.0 | 0.8 ± 0.2 | 1.25 | 0.62 | |
| ALT (UA) | M | 55.2 ± 12.9 | 50.8 ± 3.2 | 54.3 ± 4.6 | 63.1 ± 9.1 | 43.4 ± 2.5 | 43.9 ± 4.0 | – | – |
| F | 32.1 ± 1.8 | 34.6 ± 1.8 | 48.0 ± 4.2 | 54.6 ± 3.0 | 45.6 ± 3.1 | 44.2 ± 5.2 | 1.36 | 1.33 | |
| AP(UA) | M | 193.4 ± 16.0 | 217.2 ± 12.5 | 214.5 ± 17.6 | 275.9 ± 36.5 | 260.4 ± 35.8 | 212.5 ± 19.2 | – | – |
| F | 108.8 ± 6.9 | 158.3 ± 11.0 | 197.4 ± 23.2 | 213.7 ± 14.6 | 219.9 ± 19.1 | 132.2 ± 11.0 | 1.84 | 0.38 | |
| Protein (g/1) | M | 61.4 ± 0.8 | 57.7 ± 1.3 | 59.2 ± 1.0 | 61.3 ± 1.0 59.9 ± 1.3 | 59.9 ± 1.3 | 62.4 ± 1.1 | – | – |
| F | 66.9 ± 1.9 | 61.6 ± 1.5 | 60.1 ± 1.1 | 55.7 ±1.1 | 56.7 ± 0.5 | 61.9 ± 2.6 | 1.71 | 0.98 | |
Values represent means ± standard error.
Statistically significantly different from sham, p ≤ 0.05.
EECRs were calculated on an equal TPM basis.
–: no EECR calculated because data did not fit the criteria.
AP: alkaline phosphatase activity.
ALT: alanine aminotransferase activity.
Characterization of test atmospheres*: pulmonary inflammation study
| Parameter | Sham | 1R4F-450 | 1R4F-600 | EHC-AMP-750 |
|---|---|---|---|---|
| TPM (μg/l) | <4.0 | 448 ± 30 | 603 ± 41 | 739 ± 38 |
| Carbon monoxide (ppm) | <1.5 | 505 ± 34 | 656 ± 47 | 74.1 ± 5.4 |
| Nicotine (μg/l) | <0.11 | 31 ± 2.0 | 41 ± 3.1 | 65.1 ± 3.1 |
| Formaldehyde (ppm) | – | 0.58 ± 0.04 | 0.75 ± 0.05 | 0.83 ± 0.17 |
| Acetaldehyde (ppm) | – | 20 ± 0.6 | 27 ± 20 | 18 ± 1.2 |
| Acrolein | – | 1.5 ± 0.1 | 1.9 ± 0.1 | 2.0 ± 0.10 |
Measured at breathing zone in the exposure chambers.
Values represent means ± standard deviations.
Target TPM concentration (μg/l).
Differentiation of BALF cells after 90 days of exposure: pulmonary inflammation study
| Groups | |||||
|---|---|---|---|---|---|
| Parameter | Sham | 1R4F-450 | 1R4F-600 | AMP-750 | EHC-AMP-750 |
| FLC number(106) | 12.6 ± 0.8 | 16.7 ± 0.7 | 17.0 ± 0.8 | 15.6 ± 0.6 | – |
| Alveolar macrophages (106) | 12.5 ± 0.7 | 14.9 ± 0.7 | 14.0 ± 0.9 | 14.9 ± 0.6 | – |
| Alveolar macrophages (%) | 99.0 ± 0.1 | 89.2 ± 1.4 | 82.1 ± 2.2 | 95.5 ± 0.8 | – |
| Neutrophils (106) | 0.04 ± 0.008 | 1.70 ± 0.283 | 2.76 ± 0.301 | 0.63 ± 0.118 | 0.33 |
| Neutrophils (%) | 0.35 ± 0.05 | 10.13 ± 1.42 | 16.80 ± 2.14 | 3.99 ± 0.73 | 0.35 |
| Lymphocytes (106) | 0.08 ± 0.012 | 0.11 ± 0.007 | 0.18 ± 0.02 | 0.078 ± 0.007 | – |
| L | 0.65 ± 0.10 | 0.67 ± 0.05 | 1.10 ± 0.15 | 0.50 ± 0.05 | – |
Values represent means ± standard error.
Statistically significantly different from sham, p ≤ 0.05.
EECRs calculated on an equal TPM basis.
–: no EECR calculated.
FIG. 4EECR estimation for the relative number of BALF neutrophils in the inflammation study. Data points with error bars (mean values with SE of indicated exposure groups) represent percentage of neutrophils in free lung cells determined after 35 days of exposure. For the 1R4F the concentration response curve is plotted on a μg TPM/L basis. Arrows indicated the estimation of the concentration of 1R4F MS causing an effect comparable to the one of the EHC MS. The EECR is calculated by dividing the corresponding 1R4F concentration through the EHC concentration.
FIG. 5Subchronic inhalation toxicity effects of the EHC compared to the 1R4F. Summarized EECRs on a μg TPM/L basis from male and female rats for different end points combined under common toxicological perspectives. An EECR of below 1 indicates that the activity of the cigarette tested is less than that of the 1R4F.
Overview of equal effect concentration ratios for histopathological findings after 90 days of exposure: inhalation toxicity study
| EECRs | ||||
|---|---|---|---|---|
| Basis of comparison | Histopathological finding | Sex | EHC-CaCO3 | EHC-AMP |
| TPM (μg/l) | Nose | M | 1.43 | 0.20 |
| F | 1.48 | 0.40 | ||
| Larynx | M | 0.63 | 1.13 | |
| F | 0.73 | 1.02 | ||
| Lung | M | 1.16 | 0 | |
| F | 1.53 | 0.83 | ||
| Cigarette (cig./m3) | Nose | M | 0.47 | 0.05 |
| F | 0.48 | 0.12 | ||
| Larynx | M | 0.20 | 0.35 | |
| F | 0.23 | 0.30 | ||
| Lung | M | 0.38 | 0 | |
| F | 0.50 | 0.26 | ||
| Nicotine (μg/l) | Nose | M | 1.09 | 0.17 |
| F | 1.16 | 0.38 | ||
| Larynx | M | 0.51 | 0.98 | |
| F | 0.60 | 0.89 | ||
| Lung | M | 0.91 | 0 | |
| F | 1.17 | 0.75 | ||
Mean of combined findings for each organ.
Histopathology of respiratory tract organs after 90 days of exposure: inhalation toxicity study Scores of histopathological findings and laryngeal epithelial thickness
| Groups | EECRs | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | Sex | Sham | 1R4F-low | 1R4F-medium | 1R4F-high | EHC-CaCO3 | EHC-AMP | EHC-CaCO3 | EHC-AMP |
| Nose, level 1 | |||||||||
| Reserve cell hyperplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 | 3.1 ± 0.4 | – | – |
| F | 0.0 ± 0.0 | 2.2 ± 0.2 | 2.6 ± 0.3 | 3.6 ± 0.3 | 2.4 ± 0.3 | 2.0 ± 0.0 | 1.07 | 0.85 | |
| Goblet cell hyperplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 0.6 ± 0.2 | 1.3 ± 0.2 | 1.5 ± 0.2 | 0.2 ± 0.1 | 0.4 ± 0.2 | 0.34 | 0.62 |
| F | 0.0 ± 0.0 | 0.4 ± 0.2 | 0.4 ± 0.2 | 0.7 ± 0.2 | 0.1 ± 0.1 | 0.1 ± 0.1 | – | – | |
| Loss of goblet cells (respiratory epithelium) | M | 0.0 ± 0.0 | 0.7 ± 0.2 | 1.6 ± 0.2 | 1.5 ± 0.2 | 1.9 ± 0.2 | 0.1 ± 0.1 | – | – |
| F | 0.0 ± 0.0 | 0.7 ± 0.2 | 1.6 ± 0.3 | 1.8 ± 0.1 | 1.3 ± 0.2 | 0.2 ± 0.1 | – | – | |
| Squamous metaplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 1.3 ± 0.5 | 3.1 ± 0.1 | 2.5 ± 0.4 | 2.9 ± 0.1 | 0.7 ± 0.4 | 1.85 | 0.22 |
| F | 0.4 ± 0.4 | 0.3 ± 0.3 | 2.3 ± 0.5 | 1.8 ± 0.6 | 1.1 ± 0.4 | 0.0 ± 0.0 | – | – | |
| Nose, level 2 | |||||||||
| Reserve cell hyperplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.9 ± 0.5 | 1.7 ± 0.3 | 1.1 ± 0.5 | 0.0 ± 0.0 | 1.48 | 0.43 |
| F | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.3 ± 0.3 | 0.0 ± 0.0 | 0.0 ± 0.0 | – | – | |
| Atrophy (olfactory epithelium) | M | 0.0 ± 0.0 | 0.7 ± 0.4 | 1.8 ± 0.6 | 4.0 ± 0.0 | 2.9 ± 0.6 | 0.0 ± 0.0 | 1.6 | 0 |
| F | 0.0 ± 0.0 | 0.2 ± 0.2 | 2.9 ± 0.5 | 3.7 ± 0.3 | 3.2 ± 0.3 | 0.3 ± 0.2 | 1.62 | 0.58 | |
| Squamous metaplasia (olfactory epithelium) | M | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.0 ± 0.5 | 2.1 ± 0.5 | 0.7 ± 0.4 | 0.0 ± 0.0 | – | – |
| F | 0.0 ± 0.0 | 0.1 ± 0.1 | 1.4 ± 0.4 | 1.3 ± 0.2 | 1.1 ± 0.1 | 0.0 ± 0.0 | 1.47 | 0.22 | |
| Nose, level 3 | |||||||||
| Atrophy (olfactory epithelium) | M | 0.0 ± 0.0 | 0.4 ± 0.4 | 1.6 ± 0.6 | 4.0 ± 0.0 | 2.2 ± 0.7 | 0.0 ± 0.0 | 1.49 | 0.36 |
| F | 0.0 ± 0.0 | 0.4 ± 0.4 | 3.0 ± 0.4 | 3.8 ± 0.2 | 3.2 ± 0.3 | 0.0 ± 0.0 | 1.59 | 0.26 | |
| Squamous metaplasia (olfactory epithelium) | M | 0.0 ± 0.0 | 0.3 ± 0.3 | 1.0 ± 0.5 | 3.0 ± 0.0 | 2.0 ± 0.5 | 0.0 ± 0.0 | 1.61 | 0 |
| F | 0.0 ± 0.0 | 0.2 ± 0.2 | 1.3 ± 0.3 | 2.0 ± 0.2 | 1.2 ± 0.2 | 0.0 ± 0.0 | 1.39 | 0.32 | |
| Nose, level 4 | |||||||||
| Atrophy (olfactory epithelium) | M | 0.0 ± 0.0 | 0.2 ± 0.2 | 0.7 ± 0.3 | 2.0 ± 0.0 | 1.1 ± 0.4 | 0.0 ± 0.0 | 1.52 | s0 |
| F | 0.0 ± 0.0 | 0.1 ± 0.1 | 1.6 ± 0.2 | 1.9 ± 0.1 | 1.6 ± 0.2 | 0.0 ± 0.0 | 1.57 | 0.31 | |
| Squamous metaplasia (olfactory epithelium) | M | 0.0 ± 0.0 | 0.3 ± 0.3 | 1.0 ± 0.5 | 3.0 ± 0.0 | 1.7 ± 0.5 | 0.0 ± 0.0 | 1.52 | 0 |
| F | 0.0 ± 0.0 | 0.1 ± 0.1 | 1.4 ± 0.3 | 1.6 ± 0.2 | 1.5 ± 0.4 | 0.0 ± 0.0 | 1.68 | 0.28 | |
| Larynx, base of epiglottis | M | 0.0 ± 0.0 | 4.7 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | – | – |
| Squamous metaplasia (pseudostratified epithelium) | F | 0.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | – | – |
| Hyperplasia (Squamous epithelium) | M | 0.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | – | – |
| F | 0.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | 5.0 ± 0.0 | – | – | |
| Arytenoid projections, ventral depression squamous metaplasia (cuboidal epithelium) | M | 0.0 ± 0.0 | 0.9 ± 0.3 | 1.1 ± 0.4 | 2.3 ± 0.6 | 0.9 ± 0.4 | 0.9 ± 0.3 | 1.03 | 1.06 |
| F | 0.0 ± 0.0 | 0.7 ± 0.4 | 2.4 ± 0.6 | 3.2 ± 0.6 | 0.7 ± 0.4 | 1.2 ± 0.4 | 0.73 | 1.02 | |
| Arytenoid projections, vocal cords, lower medial region hyperplasia (squamous epithelium) | M | 0.0 ± 0.0 | 2.3 ± 0.2 | 2.9 ± 0.2 | 2.4 ± 0.2 | 2.3 ± 0.2 | 2.8 ± 0.2 | – | – |
| F | 0.0 ± 0.0 | 3.0 ± 0.3 | 2.3 ± 0.3 | 2.8 ± 0.3 | 2.0 ± 0.3 | 3.2 ± 0.2 | – | – | |
| Arytenoid projections, vocal cords, upper medial region | M | 0.0 ± 0.0 | 2.0 ± 0.4 | 2.6 ± 0.7 | 2.9 ± 0.4 | 1.0 ± 0.2 | 2.1 ± 0.4 | 0.23 | 0.99 |
| Squamous metaplasia (pseudostratified epithelium) | F | 0.0 ± 0.0 | 4.6 ± 0.2 | 3.3 ± 0.4 | 3.4 ± 0.3 | 3.3 ± 0.7 | 3.3 ± 0.6 | – | – |
| Arytenoid projections, floor of the larynx | M | 0.0 ± 0.0 | 4.6 ± 0.3 | 5.0 ± 0.0 | 4.8 ± 0.2 | 4.8 ± 0.2 | 4.8 ± 0.2 | – | – |
| Squamous metaplasia (pseudostratified epithelium) | F | 0.0 ± 0.0 | 4.2 ± 0.6 | 4.8 ± 0.2 | 5.0 ± 0.0 | 5.0 ± 0.0 | 4.8 ± 0.2 | – | – |
| Arytenoid projections, vocal folds | M | 0.0 ± 0.0 | 0.8 ± 0.2 | 1.4 ± 0.2 | 1.5 ± 0.2 | 0.7 ± 0.3 | 1.2 ± 0.3 | 0.62 | 1.35 |
| Hyperplasia (squamous epithelium) | F | 0.0 ± 0.0 | 1.2 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1 | 0.9 ± 0.1 | 1.2 ± 0.2 | – | – |
| Tracheal bifurcation | |||||||||
| reserve cell hyperplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.1 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.0 | – | – |
| goblet cell hyperplasia (respiratory epithelium) | M | 0.0 ± 0.0 | 0.3 ± 0.2 | 0.4 ± 0.3 | 0.9 ± 0.4 | 0.3 ± 0.2 | 0.1 ± 0.1 | – | – |
| goblet cell hyperplasia (respiratory epithelium) | F | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.9 ± 0.3 | 0.4 ± 0.3 | 0.4 ± 0.2 | 0.2 ± 0.1 | – | – |
| Left lung | |||||||||
| Goblet cell hyperplasia (respiratory epithelium) | M | 0.6 ± 0.6 | 2.9 ± 0.5 | 3.0 ± 0.5 | 3.3 ± 0.5 | 3.0 ± 0.5 | 0.9 ± 0.4 | 1.16 | 0 |
| F | 0.4 ± 0.3 | 1.2 ± 0.6 | 2.3 ± 0.6 | 3.2 ± 0.6 | 2.6 ± 0.7 | 1.2 ± 0.6 | 1.53 | 0.83 | |
| Alveolar macrophages (respiratory epithelium) | M | 0.0 ± 0.0 | 0.8 ± 0.1 | 1.0 ± 0.2 | 1.3 ± 0.2 | 0.3 ± 0.2 | 0.1 ± 0.1 | – | – |
| F | 0.0 ± 0.0 | 0.3 ± 0.2 | 0.7 ± 0.2 | 1.3 ± 0.2 | 0.1 ± 0.1 | 0.0 ± 0.0 | – | – | |
| Larynx | |||||||||
| ventral depression (μm) | M | 7.73 ± 0.45 | 11.16 ± 0.68 | 11.66 ± 0.70 | 14.72 ± 1.74 | 11.61 ± 0.98 | 11.85 ± 0.78 | 1.14 | 1.23 |
| F | 7.95 ± 0.47 | 10.56 ± 0.71 | 15.74 ± 1.63 | 16.54 ± 1.01 | 11.22 ± 0.78 | 11.88 ± 1.09 | 0.80 | 0.95 | |
| floor of the larynx (μm) | M | 9.56 ± 0.34 | 17.51 ± 1.24 | 24.74 ± 0.53 | 21.67 ± 2.37 | 20.64 ± 1.74 | 22.73 ± 1.57 | 1.17 | 1.72 |
| F | 8.62 ± 0.11 | 18.97 ± 1.18 | 23.52 ± 1.51 | 29.29 ± 1.61 | 20.44 ± 1.29 | 24.68 ± 1.64 | 1.04 | 1.45 | |
| vocal cords (μm) | M | 18.66 ± 1.11 | 29.39 ± 1.28 | 34.39 ± 1.38 | 32.21 ± 0.89 | 29.51 ± 1.55 | 32.65 ± 1.22 | – | – |
| F | 17.42 ± 1.55 | 33.16 ± 0.94 | 32.33 ± 1.22 | 34.03 ± 1.02 | 31.93 ± 1.25 | 34.91 ± 1.44 | – | – | |
Values represent means ± standard error.
Statistically significantly different from sham, p ≥ 0.05.
EECRs were calculated on an equal TPM basis.
–: no EECR calculated because data did not fit the criteria.